ONCSQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ONCSQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. OncoSec Medical's annualized Gross Profit for the quarter that ended in Jan. 2023 was $0.00 Mil. OncoSec Medical's average Total Assets over the quarter that ended in Jan. 2023 was $11.66 Mil. Therefore, OncoSec Medical's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2023 was 0.00%.
The historical data trend for OncoSec Medical's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSec Medical Annual Data | |||||||||||||||||||||
Trend | Jul13 | Jul14 | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | |||||||||||
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | - | - | - | - | - |
OncoSec Medical Quarterly Data | ||||||||||||||||||||
Apr18 | Jul18 | Oct18 | Jan19 | Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | |
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, OncoSec Medical's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, OncoSec Medical's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where OncoSec Medical's Gross-Profit-to-Asset % falls into.
OncoSec Medical's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jul. 2022 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Jul. 2022 ) | / | ( (Total Assets (A: Jul. 2021 ) | + | Total Assets (A: Jul. 2022 )) | / count ) |
= | 0 | / | ( (56.276 | + | 21.878) | / 2 ) | |
= | 0 | / | 39.077 | ||||
= | 0.00 % |
OncoSec Medical's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2023 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Jan. 2023 ) | / | ( (Total Assets (Q: Oct. 2022 ) | + | Total Assets (Q: Jan. 2023 )) | / count ) |
= | 0 | / | ( (14.439 | + | 8.871) | / 2 ) | |
= | 0 | / | 11.655 | ||||
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jan. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of OncoSec Medical's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert J Delaversano | officer: Principal Accounting Officer | 217 W. MAIN STREET, SOMERVILLE NJ 08876 |
Spahr Stephany Foster | director | C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
Robert H. Arch | officer: President and CEO | C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
George Chi | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Lin Shi | director | 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218 |
Margaret Dalesandro | director | ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
Yuhang Zhao | director | 6 HORTON DR., CHESTER NJ 07930 |
Brian A Leuthner | officer: Chief Operating Officer | 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
Daniel J. O'connor | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
China Grand Pharmaceutical & Healthcare Holdings Ltd | 10 percent owner, other: See Remarks | UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000 |
Alpha Holdings, Inc. | director, 10 percent owner | GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016 |
Kellie Malloy Foerter | officer: Chief Operating Officer | C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218 |
Herbert Kim Lyerly | director | C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218 |
Chao Zhou | director | UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000 |
Grand Decade Developments Ltd | 10 percent owner, other: See Remarks | UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000 |
From GuruFocus
By PRNewswire PRNewswire • 02-22-2022
By PRNewswire PRNewswire • 07-04-2022
By PRNewswire PRNewswire • 05-18-2023
By PRNewswire PRNewswire • 11-15-2022
By PRNewswire PRNewswire • 03-02-2023
By PRNewswire PRNewswire • 12-17-2021
By PRNewswire PRNewswire • 07-14-2021
By PRNewswire PRNewswire • 04-27-2023
By PRNewswire PRNewswire • 07-12-2022
By PRNewswire PRNewswire • 07-26-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.